EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: A case–control study of overall survival
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):